C-ZXR8General Proximity
proximity therapeutics, effector discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-ZXR8
C-ZXR8C-ZXR8proximity therapeutics, effector discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
General Proximity proximity therapeutics, effector discovery
General Proximity says it has built a generalized, mechanism-agnostic proximity discovery engine. Its platform discovers proximity mechanisms between target and effector proteins to enable activation, refolding, re-localization, re-programming, functional modulation, degradation, and other biology. The company focuses on developing proximity therapeutics for targets previously beyond the reach of medicine.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
General Proximity — Far from goals · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: exploratory. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic